Results 21 to 30 of about 436,093 (357)

Genomic Classification and Prognosis in Acute Myeloid Leukemia.

open access: yesNew England Journal of Medicine, 2016
BACKGROUND Recent studies have provided a detailed census of genes that are mutated in acute myeloid leukemia (AML). Our next challenge is to understand how this genetic diversity defines the pathophysiology of AML and informs clinical practice ...
E. Papaemmanuil   +26 more
semanticscholar   +1 more source

Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells

open access: yesHaematologica, 2011
Background The World Health Organization separates acute erythroid leukemia (erythropoiesis in ≥50% of nucleated bone marrow cells; ≥20% myeloblasts of non-erythroid cells) from other entities with increased erythropoiesis – acute myeloid leukemia with ...
Ulrike Bacher   +5 more
doaj   +1 more source

Acute Myeloid Leukemia

open access: yesHematology, 2004
AbstractAdvances in our understanding of the pathophysiology of acute myeloid leukemia (AML) have not yet led to major improvements in disease-free and overall survival of adults with this disease. Only about one-third of those between ages 18–60 who are diagnosed with AML can be cured; disease-free survival is rare and current therapy devastating in ...
Richard M, Stone   +2 more
openaire   +4 more sources

Progress in Acute Myeloid Leukemia [PDF]

open access: yesClinical Lymphoma Myeloma and Leukemia, 2015
Significant progress has been made in the treatment of acute myeloid leukemia (AML). Steady gains in clinical research and a renaissance of genomics in leukemia have led to improved outcomes. The recognition of tremendous heterogeneity in AML has allowed individualized treatments of specific disease entities within the context of patient age ...
Kadia, Tapan M   +4 more
openaire   +5 more sources

NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia

open access: yesHaematologica, 2008
Acute myeloid leukemia carrying NPM1 mutations and cytoplasmic nucleophosmin (NPMc+ acute myeloid leukemia) represents one-third of adult AML (50–60% of all acute myeloid leukemia with normal karyotype) and shows distinct biological, pathological and ...
Brunangelo Falini   +12 more
doaj   +1 more source

Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients

open access: yesHaematologica, 2012
Background The hypocellular variant of acute myeloid leukemia accounts for less than 10% of all cases of adult acute myeloid leukemia. It is defined by having less than 20 percent of cellular bone marrow in a biopsy at presentation.
Aref Al-Kali   +10 more
doaj   +1 more source

Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia

open access: yesHaematologica, 2010
Background C-type lectin-like molecule-1 is a transmembrane receptor expressed on myeloid cells, acute myeloid leukemia blasts and leukemic stem cells.
Xiaoxian Zhao   +6 more
doaj   +1 more source

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.

open access: yesBlood, 2019
Older patients with acute myeloid leukemia (AML) respond poorly to standard induction therapy. B-cell lymphoma 2 (BCL-2) overexpression is implicated in survival of AML cells and treatment resistance.
C. Dinardo   +15 more
semanticscholar   +1 more source

NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.

open access: yesThe Journal of the National Comprehensive Cancer Network, 2021
The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regarding ...
D. Pollyea   +33 more
semanticscholar   +1 more source

Dendrogenin A drives LXR to trigger lethal autophagy in cancers

open access: yesNature Communications, 2017
Dendrogenin A, cholesterol metabolite, has tumor suppressive properties but the mechanisms are unknown. Here the authors show that Dendrogenin A can induce autophagy-mediated cell death in both melanoma and acute myeloid leukaemia.
Gregory Segala   +34 more
doaj   +1 more source

Home - About - Disclaimer - Privacy